Ross A. Baker, PhD, MBA
- 12Articles
- 48.1KReads
- 2008–2016Active
- 45Collaborators
- 233Citations
About
Ross A. Baker, PhD, MBA, has contributed extensively to research on major depressive disorder, bipolar disorder, schizophrenia, and schizoaffective disorders, with a focus on adjunctive treatments involving brexpiprazole and aripiprazole. His work also encompasses metabolic disorders, cardiology, and sexual dysfunction in psychiatric populations. Baker’s publications include clinical trials and post hoc analyses examining treatment effects, metabolic outcomes, and functional improvements in patients with mood and psychotic disorders.
Publications
Improvement in Functional Outcomes With Adjunctive Aripiprazole Versus Placebo in Major Depressive Disorder: A Pooled Post Hoc Analysis of 3 Short-Term Studies
December 20, 2012
Beneficial Effects of Adjunctive Aripiprazole in Major Depressive Disorder Are Not Dependent on Antidepressant Therapy History: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Trials
November 22, 2012
Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis and the Predictive Value of Week 2 Early Response
May 31, 2012
Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Studies
January 13, 2011
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
